Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LINACLOTIDE vs TRULANCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.
Guanylate cyclase-C receptor agonist; increases intracellular c GMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.
Irritable bowel syndrome with constipation (IBS-C),Chronic idiopathic constipation (CIC)
Chronic idiopathic constipation (CIC),Irritable bowel syndrome with constipation (IBS-C)
145 mcg orally once daily, at least 30 minutes before the first meal of the day.
3 mg orally once daily.
Approximately 9–10 hours (terminal half-life in plasma), supporting once-daily dosing.
Terminal elimination half-life is approximately 16 hours, supporting once-daily dosing.
Minimally metabolized; primarily degraded by intestinal peptidases. Not a substrate for CYP450 enzymes.
Metabolized by hydrolysis and reduction, not via cytochrome P450; converted to active and inactive metabolites.
Primarily fecal as intact peptide (95%); renal excretion of absorbed drug is minimal (<5%).
Primarily excreted in feces as unchanged drug (approximately 60%) and as metabolites; renal excretion is minimal (<3%).
Approximately 94% bound to plasma proteins (primarily albumin).
Approximately 95% bound to plasma proteins, primarily albumin.
~5.2 L/kg (large Vd indicating extensive tissue distribution).
Volume of distribution is approximately 2.3 L/kg, indicating extensive tissue distribution.
Oral: ~0.1% (extremely low due to extensive degradation in GI tract and first-pass metabolism).
Absolute bioavailability is approximately 19% after oral administration due to first-pass metabolism.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease on dialysis.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C).
No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C); use not recommended.
Not approved for use in pediatric patients; safety and efficacy not established.
Safety and efficacy not established in pediatric patients below 18 years of age.
No specific dose adjustment; caution advised due to potential increased sensitivity or gastrointestinal effects, but no pharmacokinetic differences observed in elderly vs younger adults.
No specific dose adjustment recommended; however, consider potential increased sensitivity and monitor renal function due to age-related decline.
No boxed warning.
Not applicable.
Not recommended in pediatric patients; avoid use in patients with known or suspected mechanical gastrointestinal obstruction.,May cause diarrhea, which can be severe; instruct patients to discontinue if severe diarrhea occurs.,Use caution in patients with inflammatory bowel disease (Crohn's, ulcerative colitis) or a history of colonic obstruction.
Risk of diarrhea, sometimes severe; avoid in patients with suspected or known mechanical gastrointestinal obstruction; caution in patients with severe hepatic impairment.
Known or suspected mechanical gastrointestinal obstruction.,History of a serious hypersensitivity reaction to linaclotide or any component of the formulation.
Known or suspected mechanical gastrointestinal obstruction; pediatric patients <2 years of age; hypersensitivity to linaclotide or any component of the formulation.
Food reduces the efficacy of linaclotide; administer at least 30 minutes before a meal. Avoid taking with high-fat meals as they may delay gastric emptying and reduce drug effect. No specific dietary restrictions but maintaining adequate hydration is recommended due to possible diarrhea.
No significant food interactions; can be taken with or without food.
Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low due to negligible systemic exposure.
No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly needed.
Linaclotide is minimally absorbed systemically; its active metabolite is not measurable in plasma. No data on presence in human milk. M/P ratio unknown; likely low risk due to poor oral bioavailability and large molecular size.
No data on presence in human milk, effects on breastfed infant, or milk production. Exercise caution; consider developmental and health benefits of breastfeeding alongside maternal need for TRULANCE.
No dose adjustment needed; pharmacokinetic changes in pregnancy do not affect systemic exposure due to negligible absorption.
No dose adjustment recommended based on pharmacokinetic changes; however, clinical data are lacking.
Linaclotide is a guanylate cyclase-C agonist approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Onset of action can occur within 24 hours but maximal effect may take 1-2 weeks. Contraindicated in pediatric patients under 6 years due to risk of severe diarrhea. Avoid use in patients with mechanical gastrointestinal obstruction. Monitor for diarrhea, which may require dose reduction or discontinuation. Capsules should be swallowed whole; do not crush or chew. For patients with difficulty swallowing, capsules may be opened and sprinkled on applesauce or mixed in water for immediate consumption. Renal or hepatic impairment does not require dose adjustment. Linaclotide is not systemically absorbed (active locally).
Trulance (plecanatide) is a guanylate cyclase-C agonist indicated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It increases intestinal fluid and transit. Avoid use in patients younger than 6 years due to risk of severe dehydration. Dose is 3 mg once daily; no adjustment for renal or hepatic impairment. Onset may take days to weeks. Titration not needed.
Take linaclotide on an empty stomach, at least 30 minutes before the first meal of the day.,Swallow capsules whole; do not crush, chew, or break. If needed, open capsule and mix contents with applesauce or water and take immediately.,Do not take within 1 hour of eating or if you have a bowel obstruction.,Common side effects include diarrhea, which may be severe. Stop the medication and contact your doctor if you experience persistent or severe diarrhea.,Do not use in children under 6 years old.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.
Take Trulance once daily with or without food.,Swallow tablet whole; do not crush or chew.,Diarrhea is the most common side effect; report severe or persistent diarrhea.,May cause dehydration; drink adequate fluids.,Not recommended in children under 6 years.,Store at room temperature; keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LINACLOTIDE vs TRULANCE, answered by our medical review team.
LINACLOTIDE is a Guanylate Cyclase-C Agonist that works by Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.. TRULANCE is a Guanylate Cyclase-C Agonist that works by Guanylate cyclase-C receptor agonist; increases intracellular c GMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LINACLOTIDE and TRULANCE depend on the specific clinical indication. These are both Guanylate Cyclase-C Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LINACLOTIDE is: 145 mcg orally once daily, at least 30 minutes before the first meal of the day.. The standard adult dose of TRULANCE is: 3 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LINACLOTIDE and TRULANCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LINACLOTIDE is classified as Category C. Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low. TRULANCE is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.